Copyright
©2010 Baishideng.
World J Gastroenterol. Aug 7, 2010; 16(29): 3697-3703
Published online Aug 7, 2010. doi: 10.3748/wjg.v16.i29.3697
Published online Aug 7, 2010. doi: 10.3748/wjg.v16.i29.3697
Table 1 Antibodies, suppliers and clones used for immunohistochemical analysis
Marker | Supplier | Clone |
Mismatch repair system proteins | ||
Mlh1 | BD PharMingen | G168-15 |
Msh2 | Oncogene | FE11 |
Msh6 | BD Transduction Lab. | 44 |
Apoptosis | ||
Bcl-2 | DAKO | 124 |
Cell adhesion | ||
β-catenin | BD Transduction Lab. | 14 |
E-cadherin | Zymed | 4A2C7 |
Cell cycle markers | ||
Chk2 | Novocastra | DCS 270.1 |
Cyclin A | Novocastra | 6E6 |
Cyclin D1 | NeoMarkers | SP4-rabbit |
Cyclin D3 | Novocastra | DCS-22 |
Cyclin E | Novocastra | 13A3 |
p16 | Santa Cruz | F-12 |
p21 (WAF1) | Oncogene | EA10 |
p27 | BD Transduction Lab. | 57 |
RB-P | Santa Cruz | Poli-rabbit |
Skp2 | Zymed | 1G12E9 |
Cdk2 | NeoMarkers | 8D4 |
Proliferation | ||
p53 | Novocastra | DO-7 |
Ki-67 | DAKO | MIB-1 |
Others | ||
CK20 | DAKO | Ks20.8 |
RAD50 | Abcam | 2C6 |
SMAD4 | Santa Cruz | B8 |
Table 2 Clinical, pathological, and familial characteristics of the global group and the microsatellite stable and microsatellite instability groups n (%)
Global | MSS | MSI | P (χ2) | |
Patients | 45 (100) | 29 (69)1 | 13 (31)1 | |
Median age of onset (range, yr) | 39 (25-45) | 41 (25-45) | 37 (32-42) | 0.032 |
Sex | ||||
Male | 23 (51) | 13 (45) | 7 (54) | |
Female | 22 (49) | 16 (55) | 6 (46) | NS |
Location | ||||
Right colon | 20 (45) | 11 (38) | 9 (69) | |
Left colon | 15 (33) | 11 (38) | 2 (16) | |
Rectum | 10 (22) | 7 (24) | 2 (15) | NS |
Tumor differentiation | ||||
Well | 2 (4) | 2 (7) | 0 (0) | |
Moderate | 36 (80) | 23 (79) | 10 (77) | |
Poor | 7 (16) | 4 (14) | 3 (23) | NS |
Mucin production | 15 (33) | 5 (17) | 5 (39) | NS |
“Signet ring” cells | 4 (9) | 0/29 (0) | 4/13 (30) | 0.006 |
Modified Astler Coller stage | ||||
A | 3 (7) | 2 (7) | 0 (0) | |
B | 17 (38) | 12 (41) | 5 (39) | |
C | 15 (33) | 7 (24) | 6 (46) | |
D | 10 (22) | 8 (28) | 2 (15) | NS |
Associated polyps during follow-up | 15 (33) | 10 (35) | 4 (31) | NS |
Synchronous or metachronous CRCs | 3 (7) | 1 (3) | 1 (8) | NS |
Familial history of cancer | ||||
Lynch-related neoplasms in family | 18 (40) | 5 (17) | 11 (85) | < 0.01 |
Lynch unrelated neoplasms | 12 (27) | 8 (28) | 7 (54) | 0.02 |
Sporadic cases | 27 (60) | 24 (83) | 2 (15) | < 0.001 |
Table 3 Immunohistochemical study of the global group1n (%)
Normal expression | Lack of expression | |
Mismatch repair system proteins | ||
Mlh1 | 24 (86) | 4 (14) |
Msh2 | 24 (86) | 4 (14) |
Msh6 | 23 (88) | 3 (12) |
Apoptosis | ||
Bcl-2 | 7 (25) | 21 (75) |
Cell adhesion | ||
β-catenin | ||
Membrane | 24 (86) | 4 (14) |
Nucleus | 10 (36) | 18 (64) |
E-cadherin | 19 (73) | 7 (27) |
Cell cycle markers | ||
Chk2 | 13 (54) | 11 (46) |
Cyclin A | 13 (46) | 15 (54) |
Cyclin D1 | 12 (43) | 16 (57) |
Cyclin D3 | 12 (43) | 16 (57) |
Cyclin E | 8 (30) | 19 (70) |
p16 | 13 (48) | 14 (52) |
p21 | 14 (56) | 11 (44) |
p27 | 12 (52) | 11 (48) |
RB-P | 13 (48) | 14 (52) |
Skp2 | 12 (46) | 14 (54) |
Cdk2 | 13 (48) | 14 (52) |
Proliferation | ||
p53 | 15 (54) | 13 (46) |
Ki-67 | 17 (63) | 6 (37) |
Others | ||
CK20 | 10 (59) | 7 (41) |
RAD50 | 10 (63) | 6 (37) |
SMAD4 | 13 (54) | 11 (46) |
Table 4 Comparison of the immunohistochemical analyses of microsatellite stable and microsatellite instability groups n (%)
IHC expression | P | ||||
MSS | MSI | ||||
Normal | Lack | Normal | Lack | ||
MMR system proteins | |||||
Mlh1 | 20 (100) | 0 (0) | 4 (50) | 4 (50) | 0.010 |
Msh2 | 21 (100) | 0 (0) | 3 (43) | 4 (57) | 0.002 |
Ms6 | 21 (100) | 0 (0) | 2 (40) | 3 (60) | 0.004 |
Apoptosis | |||||
Bcl-2 | 5 (24) | 16 (76) | 2 (29) | 5 (71) | NS |
Cell adhesion | |||||
β-catenin | |||||
Membrane | 18 (86) | 3 (14) | 6 (86) | 1 (14) | NS |
Nucleus | 8 (38) | 13 (62) | 2 (29) | 5 (71) | NS |
E-cadherin | 15 (75) | 5 (25) | 4 (60) | 2 (40) | NS |
Cell cycle markers | |||||
Chk2 | 10 (53) | 9 (47) | 4 (60) | 2 (40) | NS |
Cyclin A | 8 (38) | 13 (62) | 5 (71) | 2 (29) | NS |
Cyclin D1 | 7 (33) | 14 (67) | 5 (71) | 2 (29) | NS |
Cyclin D3 | 8 (38) | 13 (62) | 4 (57) | 3 (43) | NS |
Cyclin E | 3 (14) | 18 (86) | 5 (83) | 1 (17) | 0.004 |
p16 | 9 (43) | 12 (57) | 4 (67) | 2 (33) | NS |
p21 | 10 (53) | 9 (47) | 4 (67) | 2 (33) | NS |
p27 | 8 (44) | 10 (56) | 4 (80) | 1 (20) | NS |
RB-P | 11 (55) | 9 (45) | 2 (29) | 5 (71) | NS |
Skp2 | 9 (43) | 12 (57) | 3 (60) | 2 (40) | NS |
Cdk2 | 9 (43) | 12 (57) | 4 (67) | 2 (33) | NS |
Proliferation | |||||
p53 | 11 (52) | 10 (48) | 5 (57) | 3 (43) | NS |
Ki-67 | 14 (67) | 7 (33) | 3 (50) | 3 (50) | NS |
Others | |||||
CK20 | 9 (75) | 3 (25) | 1 (20) | 4 (80) | NS |
RAD50 | 9 (75) | 3 (25) | 1 (25) | 3 (75) | NS |
SMAD4 | 11 (55) | 9 (45) | 2 (50) | 2 (50) | NS |
- Citation: Perea J, Alvaro E, Rodríguez Y, Gravalos C, Sánchez-Tomé E, Rivera B, Colina F, Carbonell P, González-Sarmiento R, Hidalgo M, Urioste M. Approach to early-onset colorectal cancer: Clinicopathological, familial, molecular and immunohistochemical characteristics. World J Gastroenterol 2010; 16(29): 3697-3703
- URL: https://www.wjgnet.com/1007-9327/full/v16/i29/3697.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i29.3697